AMPH vs FTRE

AMPH exhibits strong deterministic health with a Piotroski F-Score of 7/9, indicating solid operational efficiency and financial stability, though the absence of an Altman Z-Score raises concern about default risk. The stock trades at a discount to its Graham Number ($28.09) and intrinsic value ($14.21), suggesting undervaluation on a defensive basis. However, this is overshadowed by deteriorating fundamentals: negative revenue and earnings growth (YoY -1.8% and -31.0%), declining quarterly earnings, and a significant 36.4% drop in price over the past month. Insider selling activity further undermines confidence, with $0.95M in sales over six months despite no buy activity.

FTRE exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 2/9, indicating poor financial health and operational deterioration. While valuation metrics like Price/Sales (0.32) and PEG (0.34) suggest the stock is deeply undervalued, this is offset by negative revenue growth (-5.20%), a negative ROE of -102.41%, and a current ratio below 1.0 (0.98), signaling liquidity risks. Despite a 'Buy' consensus from analysts with a target of $13.21, the combination of C-suite insider selling and a consistent failure to meet earnings estimates suggests a high-risk profile.